References
- Blumenschein G, Heymach JV. Angiogenesis inhibitors for lung cancer: Clinical developments and future directions. J Thorac Oncol 2006;1:744–8.
- Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future trial development. Nat Rev Drug Discov 2007;6:734–45.
- Liu X, Wang W, Li J, Tang C, Yu F. Sunitinib in treatment of advanced non-small cell lung cancer after failure of multiregimens of chemotherapy and EGFR-TKI. J Clin Oncol 2010 ASCO Annual Meeting Proceedings 2010:e18139.
- Socinski MA. The current status and evolving role of sunitinib in non-small cell lung cancer. J Thorac Oncol 2008;3: S119–23.
- Wolter P, Beuselinck B, Pans S, Schöffski P. Flare up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta Oncol 2009;4:621–4.
- Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, . The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol 2009;6:927–31.